SCHAEYBROECK, Van, S ROLFO, CD ELEZ, E KELLY, S HOULDEN, J COLLINS, L LOVE, S ANDRE, T LAWLER, M Di NICOLANTONIO, F GRAYSON,
Vlad POPOVICI, VC BARDELLI, A LAURENT-PUIG, P SALTO-TELLEZ, M MAUGHAN, T TABERNERO, J PEETERS, M WILSON, RH MIDDLETON a MR. MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Journal of clinical oncology. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA: AMER SOC CLINICAL ONCOLOGY, 2015, roč. 33, č. 15, s. "Amer Soc Clin Oncol"-"0", 1 s. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps3632.